198 related articles for article (PubMed ID: 32754162)
1. The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions.
Jewett A
Front Immunol; 2020; 11():1692. PubMed ID: 32754162
[TBL] [Abstract][Full Text] [Related]
2. Novel Coronavirus SARS-CoV-2 Target and Disable Natural Killer Cells: Core Immune Effectors for Fighting the Disease.
Jewett A
Crit Rev Immunol; 2020; 40(2):167-171. PubMed ID: 32749094
[TBL] [Abstract][Full Text] [Related]
3. Lymphopenia in COVID-19: Therapeutic opportunities.
Fathi N; Rezaei N
Cell Biol Int; 2020 Sep; 44(9):1792-1797. PubMed ID: 32458561
[TBL] [Abstract][Full Text] [Related]
4. Conserved HLA binding peptides from five non-structural proteins of SARS-CoV-2-An in silico glance.
Marchan J
Hum Immunol; 2020; 81(10-11):588-595. PubMed ID: 32888767
[TBL] [Abstract][Full Text] [Related]
5. Long-term infection of SARS-CoV-2 changed the body's immune status.
Lin L; Luo S; Qin R; Yang M; Wang X; Yang Q; Zhang Y; Wang Q; Zhu R; Fan H; Wang H; Hu Y; Wang L; Hu D
Clin Immunol; 2020 Sep; 218():108524. PubMed ID: 32659373
[TBL] [Abstract][Full Text] [Related]
6. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.
Mazzoni A; Salvati L; Maggi L; Capone M; Vanni A; Spinicci M; Mencarini J; Caporale R; Peruzzi B; Antonelli A; Trotta M; Zammarchi L; Ciani L; Gori L; Lazzeri C; Matucci A; Vultaggio A; Rossi O; Almerigogna F; Parronchi P; Fontanari P; Lavorini F; Peris A; Rossolini GM; Bartoloni A; Romagnani S; Liotta F; Annunziato F; Cosmi L
J Clin Invest; 2020 Sep; 130(9):4694-4703. PubMed ID: 32463803
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 pneumonia: CD8
Jiang Y; Wei X; Guan J; Qin S; Wang Z; Lu H; Qian J; Wu L; Chen Y; Chen Y; Lin X
Clin Immunol; 2020 Sep; 218():108516. PubMed ID: 32574709
[TBL] [Abstract][Full Text] [Related]
8. Single-cell landscape of immunological responses in patients with COVID-19.
Zhang JY; Wang XM; Xing X; Xu Z; Zhang C; Song JW; Fan X; Xia P; Fu JL; Wang SY; Xu RN; Dai XP; Shi L; Huang L; Jiang TJ; Shi M; Zhang Y; Zumla A; Maeurer M; Bai F; Wang FS
Nat Immunol; 2020 Sep; 21(9):1107-1118. PubMed ID: 32788748
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Spike 1 Protein Controls Natural Killer Cell Activation via the HLA-E/NKG2A Pathway.
Bortolotti D; Gentili V; Rizzo S; Rotola A; Rizzo R
Cells; 2020 Aug; 9(9):. PubMed ID: 32859121
[TBL] [Abstract][Full Text] [Related]
10. Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2.
Yao Z; Zheng Z; Wu K; Junhua Z
Aging (Albany NY); 2020 May; 12(9):7639-7651. PubMed ID: 32364527
[TBL] [Abstract][Full Text] [Related]
11. Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19.
Demaria O; Carvelli J; Batista L; Thibult ML; Morel A; André P; Morel Y; Vély F; Vivier E
Cell Mol Immunol; 2020 Sep; 17(9):995-997. PubMed ID: 32612152
[No Abstract] [Full Text] [Related]
12. Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies.
Market M; Angka L; Martel AB; Bastin D; Olanubi O; Tennakoon G; Boucher DM; Ng J; Ardolino M; Auer RC
Front Immunol; 2020; 11():1512. PubMed ID: 32655581
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics and Immune Injury Mechanisms in 71 Patients with COVID-19.
Wu Y; Huang X; Sun J; Xie T; Lei Y; Muhammad J; Li X; Zeng X; Zhou F; Qin H; Shao L; Zhang Q
mSphere; 2020 Jul; 5(4):. PubMed ID: 32669467
[TBL] [Abstract][Full Text] [Related]
14. Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.
Abid MB; Mughal M; Abid MA
JAMA Oncol; 2020 Oct; 6(10):1529-1530. PubMed ID: 32433719
[No Abstract] [Full Text] [Related]
15. Immunological and inflammatory profiles in mild and severe cases of COVID-19.
Song JW; Zhang C; Fan X; Meng FP; Xu Z; Xia P; Cao WJ; Yang T; Dai XP; Wang SY; Xu RN; Jiang TJ; Li WG; Zhang DW; Zhao P; Shi M; Agrati C; Ippolito G; Maeurer M; Zumla A; Wang FS; Zhang JY
Nat Commun; 2020 Jul; 11(1):3410. PubMed ID: 32641700
[TBL] [Abstract][Full Text] [Related]
16. COVID-19: Coronavirus replication, pathogenesis, and therapeutic strategies.
Bergmann CC; Silverman RH
Cleve Clin J Med; 2020 Jun; 87(6):321-327. PubMed ID: 32366502
[No Abstract] [Full Text] [Related]
17. Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19).
Laterre PF; François B; Collienne C; Hantson P; Jeannet R; Remy KE; Hotchkiss RS
JAMA Netw Open; 2020 Jul; 3(7):e2016485. PubMed ID: 32697322
[TBL] [Abstract][Full Text] [Related]
18. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
19. Convalescent donor SARS-COV-2-specific cytotoxic T lymphocyte infusion as a possible treatment option for COVID-19 patients with severe disease has not received enough attention till date.
Hanley B; Roufosse CA; Osborn M; Naresh KN
Br J Haematol; 2020 Jun; 189(6):1062-1063. PubMed ID: 32369628
[No Abstract] [Full Text] [Related]
20. Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.
Möhn N; Pul R; Kleinschnitz C; Prüss H; Witte T; Stangel M; Skripuletz T
Front Immunol; 2020; 11():1059. PubMed ID: 32477373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]